Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSUFW6)

Drug Name
SSR-125047 Drug Info
Synonyms
Tolrestat; TOLRESTAT; 82964-04-3; Alredase; Lorestat; Tolrestatin; Tolrestatum; Tolrestatum [Latin]; AY-27773; 2-(6-Methoxy-N-methyl-5-(trifluoromethyl)naphthalene-1-carbothioamido)acetic acid; UNII-0T93LG5NMK; AY 27773; AY-27,773; CHEMBL436; 0T93LG5NMK; CHEBI:48549; LUBHDINQXIHVLS-UHFFFAOYSA-N; N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-N-methylglycine; NCGC00183862-01; N-(6-Methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine; N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-N-methylglycine
Cross-matching ID
PubChem CID
53359
ChEBI ID
CHEMBL436
CAS Number
CAS 82964-04-3
TTD Drug ID
D0Q7QY

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glyoxylate and dicarboxylate metabolism 1.42 8.38e-1 23/30 (76.67%) CS;ACAT2;PCCA;...
Tryptophan metabolism 1.41 7.41e-1 35/42 (83.33%) AOX1;CYP1B1;ACAT2;...
Wnt signaling pathway 1.40 7.23e-1 124/166 (74.7%) MMP7;DKK1;MAPK9;...
Complement and coagulation cascades 1.39 6.89e-1 76/85 (89.41%) CLU;FGG;FGA;...
MicroRNAs in cancer 1.38 6.79e-1 146/310 (47.1%) CD44;MARCKS;CRK;...
Parathyroid hormone synthesis, secretion and action 1.37 6.57e-1 98/106 (92.45%) FGFR1;CYP24A1;RHOA;...
Nicotine addiction 1.36 6.29e-1 32/40 (80%) GABRP;CACNA1A;GRIA2;...
Tyrosine metabolism 1.35 6.13e-1 30/36 (83.33%) AOX1;ALDH3A1;GOT2;...
Cardiac muscle contraction 1.32 7.11e-1 64/87 (73.56%) COX7A1;TPM2;CYC1;...
Melanogenesis 1.32 6.79e-1 74/101 (73.27%) EDN1;PLCB4;EP300;...
Ferroptosis 1.30 7.21e-1 36/41 (87.8%) SLC7A11;CP;CYBB;...
Collecting duct acid secretion 1.29 7.46e-1 22/27 (81.48%) SLC12A7;SLC4A1;ATP6V0A4;...
Pyruvate metabolism 1.27 7.70e-1 41/47 (87.23%) ACAT2;ADH5;ALDH1B1;...
Apelin signaling pathway 1.26 7.71e-1 117/137 (85.4%) KLF2;CCN2;JAG1;...
Signaling pathways regulating pluripotency of stem cell... 1.26 7.58e-1 110/143 (76.92%) ID2;FGFR1;ID1;...
Pathways of neurodegeneration 1.25 7.84e-1 354/475 (74.53%) SNCA;DKK1;NEFM;...
Arginine biosynthesis 1.24 7.61e-1 17/22 (77.27%) CPS1;GOT2;ARG1
Nicotinate and nicotinamide metabolism 1.23 7.74e-1 25/35 (71.43%) SIRT3;NADK;AOX1;...
RNA polymerase 1.23 7.43e-1 23/31 (74.19%) POLR2L;POLR2B;POLR3F;...
mRNA surveillance pathway 1.23 7.23e-1 71/98 (72.45%) CPSF1;NUDT21;PAPOLA;...
Cushing syndrome 1.00 8.70e-1 125/155 (80.65%) PBX1;KCNK3;PLCB4;...
Chronic myeloid leukemia 1.00 8.68e-1 72/76 (94.74%) CRK;CTBP1;E2F2;...
TNF signaling pathway 0.98 8.65e-1 103/112 (91.96%) CCL20;CX3CL1;MAPK9;...
Dilated cardiomyopathy 0.98 8.59e-1 86/96 (89.58%) TPM2;ITGA8;AGT;...
Basal transcription factors 0.91 8.72e-1 37/45 (82.22%) GTF2I;GTF2IRD1;TAF2;...
Vasopressin-regulated water reabsorption 0.91 8.65e-1 40/44 (90.91%) DYNC1H1;ADCY9;RAB5B;...
Base excision repair 0.91 8.60e-1 29/33 (87.88%) POLD2;OGG1;APEX1;...
Dopaminergic synapse 0.91 8.55e-1 115/132 (87.12%) MAPK9;CACNA1A;PLCB4;...
Platelet activation 0.91 8.51e-1 106/124 (85.48%) FGG;FGA;FGB;...
Propanoate metabolism 0.90 8.47e-1 30/34 (88.24%) ACAT2;PCCA;DLD;...
Osteoclast differentiation -1.30 5.05e-1 117/127 (92.13%) PPP3R1;IFNAR2;SPI1;...
Rheumatoid arthritis -1.30 5.10e-1 78/93 (83.87%) IL11;HLA-DPA1;ATP6V1G1;...
Homologous recombination -1.31 5.12e-1 35/41 (85.37%) ATM;POLD4;SSBP1;...
Protein export -1.33 4.81e-1 17/23 (73.91%) SEC63;SPCS3;SRP9;...
Pentose and glucuronate interconversions -1.33 4.78e-1 17/34 (50%) DCXR;AKR1B10;CRYL1;...
Chemokine signaling pathway -1.35 4.41e-1 163/192 (84.9%) ADCY1;CCL25;PIK3R3;...
Hematopoietic cell lineage -1.35 4.53e-1 90/99 (90.91%) DNTT;CD55;ITGA2B;...
Measles -1.37 4.06e-1 133/139 (95.68%) STAT5A;CASP3;IRAK1;...
Steroid hormone biosynthesis -1.37 4.15e-1 43/61 (70.49%) HSD3B1;STS;DHRS11;...
Lipid and atherosclerosis -1.37 4.24e-1 190/215 (88.37%) PPP3R1;ERO1A;IL18;...
Allograft rejection -1.38 4.27e-1 32/38 (84.21%) HLA-DQB1;HLA-A;GZMB;...
Intestinal immune network for IgA production -1.39 4.23e-1 38/48 (79.17%) HLA-DPA1;IL6;HLA-DOA;...
Staphylococcus aureus infection -1.41 3.60e-1 72/95 (75.79%) DSG1;PTAFR;C5AR1;...
Autoimmune thyroid disease -1.42 3.51e-1 46/53 (86.79%) HLA-DQB1;HLA-A;GZMB;...
NF-kappa B signaling pathway -1.44 3.41e-1 90/104 (86.54%) CCL19;IKBKG;TNFAIP3;...
Other glycan degradation -1.45 3.32e-1 13/18 (72.22%) ENGASE;MAN2B1;HEXA;...
Peroxisome -1.49 2.60e-1 72/82 (87.8%) PEX2;PEX12;ACSL4;...
Phagosome -1.49 2.67e-1 118/152 (77.63%) TAP2;SEC61G;HLA-DRB1;...
Yersinia infection -1.49 2.86e-1 120/137 (87.59%) IRF3;AKT3;CDC42;...
Influenza A -1.50 2.86e-1 156/172 (90.7%) PIK3CB;MAP2K1;CASP9;...
Protein digestion and absorption -1.56 1.84e-1 78/103 (75.73%) COL9A2;MEP1B;SLC7A9;...
Type I diabetes mellitus -1.58 1.57e-1 38/43 (88.37%) GAD2;HLA-DQB1;HLA-A;...
Human immunodeficiency virus 1 infection -1.59 1.60e-1 189/212 (89.15%) PPP3R1;RPS6KB2;CUL5;...
Asthma -1.59 1.73e-1 25/31 (80.65%) HLA-DRB1;HLA-DOB;MS4A2;...
Herpes simplex virus 1 infection -1.60 1.84e-1 165/498 (33.13%) HLA-DQB1;HLA-A;PIK3R3;...
Primary immunodeficiency -1.61 1.92e-1 33/38 (86.84%) TNFRSF13B;DCLRE1C;IKBKG;...
PPAR signaling pathway -1.68 1.36e-1 66/74 (89.19%) SLC27A2;RXRG;ACOX2;...
Lysosome -1.70 1.53e-1 115/128 (89.84%) ATP6V1H;PSAP;CTSZ;...
Malaria -1.71 2.18e-1 44/50 (88%) CXCL8;SELP;TGFB1;...
Renin-angiotensin system -1.72 4.04e-1 20/23 (86.96%) ENPEP;ACE2;CPA3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 3.33uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H